Roche files MabThera for early arthritis in EU
This article was originally published in Scrip
Roche has filed its anti-CD20 monoclonal antibody MabThera (rituximab) with the EMEA to extend its label for rheumatoid arthritis (RA) to include patients who have not been treated with methotrexate; those who have had an inadequate response to methotrexate; and for the prevention of joint damage across the whole RA patient population.
You may also be interested in...
Somaxon Pharmaceuticals and Procter & Gamble Pharmaceuticals are to co-promote Somaxon's insomnia drug Silenor (low-dose doxepin) in the US.
GlaxoSmithKline has begun the Phase III clinical trials programme for its adjuvanted vaccine candidate (GSK1437173A) against herpes zoster for the prevention of shingles.
The EMA has accepted Optimer Pharmaceuticals' MAA for its narrow-spectrum antibiotic fidaxomicin for the treatment of Clostridium difficile infection (CDI) and for the prevention of recurrences of CDI.